« PreviousContinue »
Isner, J.M., etal., "Physiologic Assessment of Angiogenesis by Arterial Gene Therapy with Vascular Endothelial Growth Factor," J. Cell. Biochem. (Suppl. 21A):378, Abstract C6-215, Wiley-Liss (Mar-Apr. 1995).
Isner, J.M., "Therapeutic Angiogenesis in Vascular Medicine," Project No. R01 HL53354-01, Abstract (Mar. 1995). Joosten et al., "The production of antibody fragments and antibody fusion proteins by yeasts and filamentous fungi," Microbial Cell Fact. 2:1, BioMed Central (Jan. 2003).
Kubo, H., et al., "Blockade of vascular endothelial growth factor
receptor-3 signaling inhibits fibroblast growth factor-2-induced
lymphangiogenesis in mouse cornea," Proc. Natl. Acad. Sci.
99:8868-8873, The National Academy of Sciences (Jun. 2002).
Kuzuya, M. And Kinsella, J.L., "Induction of Endothelial Cell Dif-
ferentiation in Vitro by Fibroblast-Derived Soluble Factors," Exp.
Cell Res. 275:310-318, Academic Press, Inc. (Dec. 1994).
Longo, R., et al., "Anti-angiogenic therapy: Rationale, challenges
and clinical studies," Angiogenesis 5:237-256, Kluwer Academic
Publishers (Dec. 2002).
Maher, PA., "Stimulation of Endothelial Cell Proliferation by
Vanadate Is Specific for Microvascular Endothelial Cells," J. Cell.
Physiol. 757:549-554, Wiley-Liss, Inc. (1992).
Maynard, J. and Georgiou, G., "Antibody Engineering," Annu. Rev.
Biomed. Eng. 2:339-376, Annual Reviews (Aug. 2000).
Mesri, E.A., et al., "Expression of Vascular Endothelial Growth Fac-
tor From a Defective Herpes Simplex Virus Type 1 Amplicon Vector
Induces Angiogenesis in Mice," Circulation Res. 76:161 -167, Ameri-
can Heart Association, Inc. (Feb. 1995).
Morea, V, et al., "Antibody Modeling: Implications for Engineering and Design," Methods 20:267-279, Academic Press (Mar. 2000). Muhlhauser, J., et al., "In Vivo Gene Transfer into Porcine Cardiac Cells with a Replication-Deficient Recombinant Adenovirus Vector," Circulation 55:1-475, Abstract No. 2558, American Heart Association (Oct. 1993).
Muhlhauser, J., et al., "VEGF165 Expressed by a Replication-Deficient Recombinant Adenovirus Vector Induces Angiogenesis In Vivo," Circulation Res. 77:1077-1086, American Heart Association, Inc (Dec. 1995).
Oikawa, T., et al., "Three Isoforms of Platelet-Derived Growth Factors All Have the Capability to Induce Angiogenesis In Vivo," Biol. Pharm. Bull. 77:1686-1688, Pharmaceutical Society of Japan (Dec. 1994).
Pajusola, K., etal., "Signalling properties of FLT4, a proteolytically processed receptor tyrosine kinase related to two VEGF receptors," Oncogene 9:3545-3555, Macmillan Press Ltd. (Dec. 1994). Pepper, M.S., et al., "In Vitro Angiogenic and Proteolytic Properties ofBovine Lymphatic Endothelial Cells," Exp. CellRes. 270:298-305, Academic Press, Inc. (Jan. 1994).
Plate, K.H., "From angiogenesis to lymphangiogenesis," Nat. Med. 7:151-152, Nature America, Inc. (Feb. 2001). Schlaeppi et al., "Characterization of a new potent, in vivo neutralizing monoclonal antibody to human vascular endothelial growth factor," J Cancer Res. Clin. Oncol. 725:336-342(1999). Skerra et al., "Assembly of a functional immunoglobulin Fv fragment in Escherichia coli." Science 240:1038-1041, American Association for the Advancement of Science (1988).
Spranger, J. and Pfeiffer, A.F.H., "New concepts in pathogenesis and
treatment of diabetic retinopathy," Exp. Clin. Endocrinol. Diabetes
109(Suppl. 2):S438-S450, J.A. Barth Verlag (2001).
Symes, J.F. and Sniderman, A.D., "Angiogenesis: potential therapy
forischaemic disease," Curr. Opin. Lipidol. 5:305-312, Current Sci-
ence Ltd. (Aug. 1994).
Takeshita, S., et al., "In Vivo Evidence of Enhanced Angiogenesis
Following Direct Arterial Gene Transfer of the Plasmid Encoding
Vascular Endothelial Growth Factor," Circulation 55:1-476, Abstract
No. 2565, American Heart Association (Oct. 1993).
Takeshita, S., et al., "Therapeutic Angiogenesis. A Single Intraarte-
rial Bolus of Vascular Endothelial Growth Factor Augments
Revascularization in a Rabbit Ischemic Hind Limb Model," J. Clin.
Invest. 93:662-670, The American Society for Clinical Investigation,
Inc. (Feb. 1994).
Van Der Flier, M., et al., "Antibody neutralization of vascular endothelial growth factor (VEGF) fails to attenuate vascular permeability and brain edema in experimental pneumococcal meningitis," J. Neuroimmunol. 160:170-177, Elsevier B.V (Mar. 2005). Verma et al., "Gene therapy—promises, problems and prospects," Nature 359:239-242, Nature Publishing Company (Sep. 1997). Walsh, D.A., "Angiogenesis and arthritis," Rheumatology 35:103112, British Society for Rheumatology (Feb. 1999). Walsh, D.A. and Pearson, C.I., "Angiogenesis in the pathogenesis of inflammatory joint and lung diseases," Arthritis Res. 3:147-153, BioMed Central Ltd. (Feb. 2001).
Williams, R.S., "Southwestern Internal Medicine Conference: Prospects for Gene Therapy of Ischemic Heart Disease," Am. J. Med. Sci. 306:129-136, Lippincott Williams & Wilkins (Aug. 1993). Winkler, K., et al., "Changing the Antigen Binding Specificity by Single Point Mutations of an Anti-p24 (HIV-1) Antibody," J. Immunol. 765:4505-4514, The American Association of Immunologists (Oct. 2000).
Witzenbichler, B., et al., "Vascular Endothelial Growth Factor-C (VEGF/VEGF-2) Promotes Angiogenesis in the Setting of Tissue Ischemia," Am. J. Pathol. 753:381-394, American Society for Investigative Pathology, Inc. (Aug. 1998).
Yeung, P.K.F., "VEGF-2," Curr. Opin. Invest. Drugs 2:796-800, PharmaPress Ltd. (Jun. 2001).
NCBI Entrez, Accession No. AF010302, Mandriota S.J. and Pepper, M.S. (first available Jul. 16, 1997).
Letter from John J. Chicca II, Ph.D., Molecular Diagnostic Services, Inc. regarding a third progress report for a project entitled "Cloning and expression of VEGF-2 gene and the efficacy of VEGF-2 protein utilizing the 3-D collagen angiogenesis assay and proliferation," dated Feb. 16, 2006.
Letter from John J. Chicca II, Ph.D., Molecular Diagnostic Services, Inc. regarding a fourth progress report for a project entitled "Cloning and expression of VEGF-2 gene and the efficacy of VEGF-2 protein utilizing the 3-D collagen angiogenesis assay and proliferation," dated Mar. 14, 2006.
Dermer, G.B., "Another Anniversary for the War on Cancer," Bio/ Technol. 72:320, Wiley-VCH Verlag GmbH & Co. (Mar. 1994). Duda, D.G., etal., "VEGF-targeted cancer therapy strategies: current progress, hurdles and future prospects," Trends Molec. Med. 73(6):223-230, Elsevier Ltd. (Apr. 2007).
Gura, T., "Systems for Identifying New Drugs Are Often Faulty," Science 275(5340):1041-1042, American Association for the Advancement of Science (Nov. 1997).
Landolfi, N. F., et al., "The Integrity of the Ball-and-Socket Joint Between V and C Domains Is Essential for Complete Activity of a Humanized Antibody," J! Immunol. 766:1748-1754, The American Association of Immunologists (Feb. 2001).
Liu, Z., et al., "Fine mapping of the antigen-antibody interaction of scFv215, a recombinant antibody inhibiting RNA polymerase II from Drosophila melanogaster,"J. Mol. Recognit. 12:103-111, John Wiley & Sons, Ltd. (Mar. 1999).
U.S. Appl. No. 12/078,569, inventors Rosen et al., filed Apr. 1, 2008 (Not Published).
Alderson, R.F., et al., "Vascular Endothial Cell Growth Factor (VEGF)-2 Enhances the Development of Rat Photoreceptor Cells in Vitro," Keystone Symposia, Ocular Cell & Molec. Biol., pp. 32, Abstract No. 202, Association for Research in Vision and Ophthalmology (Feb. 1999).
Litwin, M.S., et al., "Role of Cytokines in Endothelial Cell Functions," In Human Cytokines: Their Role in Disease and Therapy. Aggarawal, B.B. andPuri, R.K., eds. Blackwell Science, Cambridge, Massachusetts, pp. 101-130 (Apr. 1995).
Shibuya, M., et al., "Nucleotide sequence and expression of a novel human receptor-type tyrosine kinase gene (fit) closely related to the fms family," Oncogene 5:519-524 (1990).
Vale, PR., et al., "Percutaneous Electromechanical Mapping Dem-
onstrates Efficacy of pVGI.l (VEGF2) in an Animal Model of
Chronic Myocardial Ischemia," Circulation Suppl. 100: 1-22,
Abstract No. 109, American Heart Association (Nov. 1999).
U.S. Appl. No. 12/258,109, inventors Rosen etal., filed Oct. 24, 2008
U.S. Appl. No. 12/258,140, inventors Alderson et al., filed Oct. 24, 2008 (Not Published).
U.S. Appl. No. 12/396,033, inventors Hu et al., filed Mar. 2, 2009 (Not Published).
Henry, M.D., et al., "A Prostate-Specific Membrane Antigen-Targeted Monoclonal Antibody-Chemotherapeutic Conjugate Designed for the Treatment of Prostate Cancer," Cancer Res., 64:7995-8001, American Association for Cancer Research (Nov. 2004). Riemer, A.B., et al., "Matching of trastuzumab (Herceptin®) epitope mimics onto the surface of Her-2/neu—a new method of epitope definition,"Mo/. Immunol., 42:1121-1124, Elsevier Ltd. (May 2004).
Roitt, I.M., et al., "IgG Structure in Relation to Function," in Immunology. Roitt, I.M., et al., eds. Gower Medical Publishing, New York, NY, pp. 5.8-5.9 (1989).
Stancovski, I., et al., "Mechanistic aspects of the opposing effects of monoclonal antibodies to the ERBB2 receptor on tumor growth," Proc. Natl. Acad. Sci. USA, 88:8691-8695, National Academy of Sciences (Oct. 1991).
Wu, H., et al., "Humanization of a Murine Monoclonal Antibody by Simultaneous Optimization of Framework and CDR Residues," J. Mol. Biol., 294:151-162, Academic Press (Nov. 1999).
* cited by examiner
GTCCTTCCACCATGCACTCGCTGGGCTTCTTCTCTGTGGCGTGTTCTCTGCTCGCCGCTG :+ + + + + +
+ + + + + +
ACCTCTCGGACGCGGAGCCCGACGCGGGCGAGGCCACGGCTTATGCAAGCAAAGATCTGG + + + +. + +
+ + + + + +
+ + ■ + --- + + +
+ + + ■ + + +
GTATAGATGTGGGGAAGGAGTTTGGAGTCGCGACAAACACCTTCTTTAAACCTCCATGTG . + + + + + +
TGTCCGTCTACAGATGTGGGGGTTGCTGCAATAGTGAGGGGCTGCAGTGCATGAACACCA + _. + + + —, + . +
GCACGAGCTACCTCAGCAAGACGTTATTTGAAATTACAGTGCCTCTCTCTCAAGGCCCCA .+ + + + + +
+ + + + + +
+ + + + + +
TGGCTCAGGAAGATTTTATGTTTTCCTCGGATGCTGGAGATGACTCAACAGATGGATTCC + + + + + +
ATGACATCTGTGGACCAAACAAGGAGCTGGATGAAGAGACCTGTCAGTGTGTCTGCAGAG + _ + + + + +
+ — * + + + ~ ■- + +